Search This Blog

Tuesday, September 19, 2023

NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug

 

  • Patents valid through 2038

  • Clinical topline results from Phase 2b ALS trial expected in H2 2023

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)